UroGen Pharma Ltd. (NASDAQ:URGN) is set to announce third quarter earning results on Monday 9th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, URGN to report 3Q20 loss of $ 1.49 per share from revenue of $ 3.34 million.
For the full year, analysts anticipate top line of $ 11.79 million, while looking forward to loss of $ 6.16 per share bottom line.
Previous Quarter Performance
UroGen Pharma Ltd. came out with loss for the second quarter of $ 1.44 per share, from the revenue of $ 0.37 million. The consensus estimates are loss of $ 1.58 per share from $ 0.26 million in revenue. The bottom line results beat street analysts by $ 0.14 or 8.86 percent, at the same time, top line results outshined analysts by $ 0.11 million or 42.31 percent.
Stock Performance
On Friday, shares of UroGen Pharma Ltd. has traded high as $ 25.42 and has cracked $ 23.37 on the downward trend, reaching $ 23.71 with volume of 88.90 thousand shares.
According to the previous trading day, closing price of $ 23.71, representing a 93.83 % increase from the 52 week low of $ 13.12 and a 27.78 % decrease over the 52 week high of $ 35.21.
The company has a market capital of $ 522.18 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
UroGen Pharma Ltd. will be hosting a conference call at 8:30 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.urogen.com
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The companys lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.
